-
11.发明申请公开(公告)号：US20200038448A1
公开(公告)日：2020-02-06
申请号：US16659347
申请日：2019-10-21
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , C07K16/28 , A61K38/08 , C07K14/47 , A61P35/00 , A61K39/39 , C07K7/06 , C07K14/54
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
12.发明公开公开(公告)号：US20230241115A1
公开(公告)日：2023-08-03
申请号：US18173177
申请日：2023-02-23
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
13.发明公开公开(公告)号：US20230241113A1
公开(公告)日：2023-08-03
申请号：US18170698
申请日：2023-02-17
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
14.发明公开公开(公告)号：US20230241108A1
公开(公告)日：2023-08-03
申请号：US18164407
申请日：2023-02-03
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
CPC classification number: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/2818 , C07K7/06 , C07K14/5434 , A61P35/02 , A61K39/001102 , A61K45/06 , C12N5/0636 , A61K39/001114 , A61K39/001118 , A61K39/12 , C07K16/244 , A61K39/39558 , C07K16/2821 , A61K38/08 , C07K14/4748 , A61K2039/5156 , A61K45/05
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210069251A1
公开(公告)日：2021-03-11
申请号：US17089502
申请日：2020-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
Patent Agency Ranking
公开(公告)号：US20210052654A1
公开(公告)日：2021-02-25
申请号：US17089486
申请日：2020-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210052653A1
公开(公告)日：2021-02-25
申请号：US17089353
申请日：2020-11-04
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20210041454A1
公开(公告)日：2021-02-11
申请号：US16988290
申请日：2020-08-07
Applicant: Immatics US, Inc. , Immatics Biotechnologies GmbH
Inventor： Chih-Chiang TSOU , Jens FRITSCHE , Toni WEINSCHENK , Julian MUELLER
Abstract: The present disclosure relates to methods of improved identification of peptides, for example, antigenic peptides. In particular, the present disclosure relates to methods of more accurately identifying human leukocyte antigen (HLA) peptides by utilizing classification systems. The disclosure also provides for utilizing the described methods for the field of personalized cancer therapies, such as adoptive cellular therapy (ACT).
-
19.发明申请公开(公告)号：US20200297772A1
公开(公告)日：2020-09-24
申请号：US16881795
申请日：2020-05-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
20.发明申请公开(公告)号：US20200297771A1
公开(公告)日：2020-09-24
申请号：US16881758
申请日：2020-05-22
Applicant: Immatics Biotechnologies GmbH
Inventor： Heiko SCHUSTER , Franziska HOFFGAARD , Jens FRITSCHE , Oliver SCHOOR , Toni WEINSCHENK , Daniel Johannes KOWALEWSKI , Chih-Chiang TSOU
IPC: A61K35/17 , A61P35/00 , A61K39/39 , C07K16/28 , C07K7/06 , C07K14/54 , A61P35/02 , A61K39/00 , A61K45/06 , C12N5/0783 , A61K39/12 , C07K16/24 , A61K39/395 , A61K38/08 , C07K14/47
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
-
-
-
-
-
-
-
-
Search Results
82
records
(took 0.05 seconds)
